Robert C Owens

Summary

Affiliation: Maine Medical Center
Country: USA

Publications

  1. doi request reprint Antimicrobial stewardship: application in the intensive care unit
    Robert C Owens
    Department of Clinical Pharmacy Services and Division of Infectious Diseases, Maine Medical Center, 22 Bramhall Street, Portland, ME 04102, USA
    Infect Dis Clin North Am 23:683-702. 2009
  2. ncbi request reprint Clostridium difficile-associated disease: changing epidemiology and implications for management
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
    Drugs 67:487-502. 2007
  3. ncbi request reprint Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 57:77S-83S. 2007
  4. ncbi request reprint Antimicrobial-associated QT interval prolongation: pointes of interest
    Robert C Owens
    Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
    Clin Infect Dis 43:1603-11. 2006
  5. doi request reprint Antimicrobial stewardship: concepts and strategies in the 21st century
    Robert C Owens
    Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 61:110-28. 2008
  6. ncbi request reprint Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists
    Robert C Owens
    Antimicrobial Stewardship Program, Departments of Pharmacy Services and Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
    Pharmacotherapy 26:299-311. 2006
  7. pmc An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?
    Robert C Owens
    Department of Clinical Pharmacy and Infectious Diseases, Maine Medical Center, Bramhall Street, Portland, Maine 04102, USA
    Crit Care 12:S3. 2008
  8. doi request reprint Antimicrobial stewardship: shepherding precious resources
    Robert C Owens
    Department of Pharmacy, and Clinical Pharmacy Specialist, Infectious Diseases, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102 3175, USA
    Am J Health Syst Pharm 66:S15-22. 2009
  9. ncbi request reprint Antimicrobial safety: focus on fluoroquinolones
    Robert C Owens
    Division of Infectious Diseases, Department of Clinical Pharmacy Services, Maine Medical Center, Portland, Maine 04102, USA
    Clin Infect Dis 41:S144-57. 2005
  10. ncbi request reprint Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 51:45-9. 2005

Detail Information

Publications31

  1. doi request reprint Antimicrobial stewardship: application in the intensive care unit
    Robert C Owens
    Department of Clinical Pharmacy Services and Division of Infectious Diseases, Maine Medical Center, 22 Bramhall Street, Portland, ME 04102, USA
    Infect Dis Clin North Am 23:683-702. 2009
    ..With pharmacists and physicians trained in infectious disease and critical care, clear-cut interventions can be focused on beginning or growing a stewardship program, or proposing future studies...
  2. ncbi request reprint Clostridium difficile-associated disease: changing epidemiology and implications for management
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
    Drugs 67:487-502. 2007
    ..Several newer therapies are under investigation but it is unclear whether they will be superior to current treatment options...
  3. ncbi request reprint Antimicrobial stewardship and the role of pharmacokinetics-pharmacodynamics in the modern antibiotic era
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 57:77S-83S. 2007
    ..In addition, general pharmacokinetic-pharmacodynamic (PK-PD) concepts will be reviewed and specific PK-PD analyses that support the optimal selection, dosing, and duration of therapy for beta-lactam antimicrobials will be provided...
  4. ncbi request reprint Antimicrobial-associated QT interval prolongation: pointes of interest
    Robert C Owens
    Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
    Clin Infect Dis 43:1603-11. 2006
    ..Additionally, because TdP remains a difficult-to-measure adverse event, we must rely upon multiple data sources to determine the risk versus the benefit for newly approved drugs...
  5. doi request reprint Antimicrobial stewardship: concepts and strategies in the 21st century
    Robert C Owens
    Department of Clinical Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 61:110-28. 2008
    ..The components of an effective ASP are described in depth, drawing examples from the literature, as well as from the author's personal experience at the Maine Medical Center, Portland, ME...
  6. ncbi request reprint Clostridium difficile-associated disease: an emerging threat to patient safety: insights from the Society of Infectious Diseases Pharmacists
    Robert C Owens
    Antimicrobial Stewardship Program, Departments of Pharmacy Services and Infectious Diseases, Maine Medical Center, Portland, Maine 04102, USA
    Pharmacotherapy 26:299-311. 2006
    ..difficile-associated disease. Efforts to combat BI/NAP1 should include good antimicrobial stewardship in addition to effective infection control and environmental intervention...
  7. pmc An overview of harms associated with beta-lactam antimicrobials: where do the carbapenems fit in?
    Robert C Owens
    Department of Clinical Pharmacy and Infectious Diseases, Maine Medical Center, Bramhall Street, Portland, Maine 04102, USA
    Crit Care 12:S3. 2008
    ..Finally, new methods of administration are being evaluated that may influence peak concentration-related antimicrobial adverse events...
  8. doi request reprint Antimicrobial stewardship: shepherding precious resources
    Robert C Owens
    Department of Pharmacy, and Clinical Pharmacy Specialist, Infectious Diseases, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102 3175, USA
    Am J Health Syst Pharm 66:S15-22. 2009
    ..Differences in antimicrobial stewardship program (ASP) strategies, evidences supporting the benefits of ASPs, barriers to implementing ASPs, and suggestions for overcoming the barriers are discussed...
  9. ncbi request reprint Antimicrobial safety: focus on fluoroquinolones
    Robert C Owens
    Division of Infectious Diseases, Department of Clinical Pharmacy Services, Maine Medical Center, Portland, Maine 04102, USA
    Clin Infect Dis 41:S144-57. 2005
    ..This review summarizes safety and tolerability data for the quinolones...
  10. ncbi request reprint Assessment of pharmacokinetic-pharmacodynamic target attainment of gemifloxacin against Streptococcus pneumoniae
    Robert C Owens
    Department of Clinical Pharmacy Services, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 51:45-9. 2005
    ..Preferential use of pharmacodynamically potent agents over other alternatives may lead to improved clinical outcomes and decreased selection of fluoroquinolone-resistant pneumococci...
  11. ncbi request reprint Antimicrobial stewardship programs as a means to optimize antimicrobial use. Insights from the Society of Infectious Diseases Pharmacists
    Robert C Owens
    Departments of Clinical Pharmacy Services Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102, USA
    Pharmacotherapy 24:896-908. 2004
    ..We review the more recent literature concerning the impact of antimicrobial stewardship programs on costs, outcomes, and resistance and summarize important considerations for implementation of these programs...
  12. ncbi request reprint QT prolongation with antimicrobial agents: understanding the significance
    Robert C Owens
    Department of Clinical Pharmacy, Maine Medical Center, Portland, 04102, USA
    Drugs 64:1091-124. 2004
    ..Incorporating information learned regarding QT interval-related adverse effects into the drug selection process may serve to minimise collateral iatrogenic toxicity...
  13. doi request reprint Rational dosing of antimicrobial agents: pharmacokinetic and pharmacodynamic strategies
    Robert C Owens
    Department of Pharmacy, and Clinical Pharmacy Specialist, Infectious Diseases, Division of Infectious Diseases, Maine Medical Center, Portland, ME 04102 3175, USA
    Am J Health Syst Pharm 66:S23-30. 2009
    ....
  14. ncbi request reprint Torsades de pointes associated with fluoroquinolones
    Robert C Owens
    Department of Clinical Pharmacy, Maine Medical Center, Portland 04102, USA
    Pharmacotherapy 22:663-8; discussion 668-72. 2002
    ..For moxifloxacin, levofloxacin, and gatifloxacin, the point must be clear that these agents should not be used in patients with risk factors predisposing them to TdP...
  15. ncbi request reprint Clinical pharmacodynamics of quinolones
    Paul G Ambrose
    Division of Infectious Diseases, Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221, USA
    Infect Dis Clin North Am 17:529-43. 2003
    ..The maturation of antimicrobial PK-PD as a scientific discipline continues to accelerate and currently impacts clinical practice, drug development, and regulatory decision making...
  16. doi request reprint Antimicrobial-associated risk factors for Clostridium difficile infection
    Robert C Owens
    Maine Medical Center, Portland, ME 04102, USA
    Clin Infect Dis 46:S19-31. 2008
    ....
  17. ncbi request reprint Stability of cefepime and metronidazole prepared for simplified administration as a single product
    Thomas D Nolin
    Department of Pharmacy Services, Maine Medical Center, Portland, ME 04102, USA
    Diagn Microbiol Infect Dis 56:179-84. 2006
    ..These data suggest that therapeutic use of cefepime and metronidazole as a single intravenous admixture product is feasible and practical...
  18. ncbi request reprint Postmarketing clinical experience in patients with skin and skin-structure infections treated with daptomycin
    Robert C Owens
    Maine Medical Center, Portland, Maine, USA
    Am J Med 120:S6-12. 2007
    ..10 days, P = 0.002). The results of this study support previously published reports and suggest that daptomycin is effective for the treatment of skin infections due to gram-positive pathogens...
  19. ncbi request reprint Optimizing antimicrobial dosing in the critically ill patient
    John Goldberg
    Department of Medicine, Division of Infectious Diseases, and Division of Critical Care Pharmacology, Maine Medical Center, Portland, Maine 04102, USA
    Curr Opin Crit Care 8:435-40. 2002
    ..In this review, we discuss some of the principles required to optimize antimicrobial dosing and recently obtained data regarding its application to the critically ill patient...
  20. ncbi request reprint Optimizing formulary choices of the fluoroquinolones
    Robert C Owens
    Antimicrobial Stewardship Program and Clinical Pharmacy Specialist, Infectious Diseases, Maine Medical Center, Portland, USA
    Manag Care Interface . 2005
  21. pmc Community transmission in the United States of a CTX-M-15-producing sequence type ST131 Escherichia coli strain resulting in death
    Robert C Owens
    Division of Infectious Diseases, Department of Medicine, Maine Medical Center, Portland, Maine, USA
    J Clin Microbiol 49:3406-8. 2011
    ..Susceptibility results (reported on day 4) showed resistance to the initially selected regimen...
  22. ncbi request reprint Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains
    Warren N Fawley
    Department of Microbiology, General Infirmary, Old Medical School, Leeds, United Kingdom
    Infect Control Hosp Epidemiol 28:920-5. 2007
    ..To compare the effects of hospital cleaning agents and germicides on the survival of epidemic Clostridium difficile strains...
  23. ncbi request reprint Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime
    Paul G Ambrose
    Cognigen Corporation, 395 Youngs Road, Buffalo, NY 14221 5831, USA
    J Antimicrob Chemother 49:445-53. 2002
    ..Moreover, sufficient clinical outcome data in infected patients exist and support these pharmacodynamic conclusions...
  24. ncbi request reprint Fluoroquinolone-associated dysglycemias: a tale of two toxicities
    Robert C Owens
    Pharmacotherapy 25:1291-5. 2005
  25. ncbi request reprint An epidemic, toxin gene-variant strain of Clostridium difficile
    L Clifford McDonald
    Epidemiology and Laboratory Branch, Division of Healthcare Quality Promotion, Centers for Disease Control and Prevention, Atlanta, USA
    N Engl J Med 353:2433-41. 2005
    ..difficile with increased virulence, resistance, or both...
  26. ncbi request reprint Hospital-based strategies for combating resistance
    Robert C Owens
    Department of Medicine, University of Vermont College of Medicine, Burlington, USA
    Clin Infect Dis 42:S173-81. 2006
    ....
  27. doi request reprint Measures to control and prevent Clostridium difficile infection
    Dale N Gerding
    Hines Veterans Affairs Hospital, Hines, IL 60141, USA
    Clin Infect Dis 46:S43-9. 2008
    ..The efficacy of metronidazole or vancomycin prophylaxis to prevent CDI in patients who are receiving other antimicrobials is unproven, and treatment with these agents is ineffective against C. difficile in asymptomatic carriers...
  28. doi request reprint Treatment of Clostridium difficile infection
    Dale N Gerding
    Hines Veterans Affairs Hospital, Hines, IL 60141, USA
    Clin Infect Dis 46:S32-42. 2008
    ..difficile vaccine...
  29. ncbi request reprint Gatifloxacin-associated corrected QT interval prolongation, torsades de pointes, and ventricular fibrillation in patients with known risk factors
    Joseph S Bertino
    Departments of Pharmacy Services and Medicine, Division of Clinical Pharmacology, Bassett Healthcare, Cooperstown, NY, 13326, USA
    Clin Infect Dis 34:861-3. 2002
    ..We report 4 cases of gatifloxacin-associated cardiac toxicity in patients with known risk factors for this adverse event...
  30. ncbi request reprint AUIC in humans: a fact-based discussion
    Guy W Amsden
    Ann Pharmacother 37:1518-21. 2003
  31. ncbi request reprint Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship
    Timothy H Dellit
    Harborview Medical Center and the University of Washington, Seattle, USA
    Clin Infect Dis 44:159-77. 2007